CURRICULUM VITAE DENNIS F. MOORE, JR., M.D., F.A.C.P.
Office Address: 818 N. Emporia, Ste, 403 Wichita, KS 67214
Office Phone: (316) 262-4467 / Fax: (316) 262-0706
Present Position: Physician, Cancer Center of Kansas Date of Hire: 07/01/94
Medical Licensure: 1990, State of Kansas
EDUCATION Year Degree Institution 8/1979-5/1982 -- Washington University, St. Louis, Missouri 8/1982-5/1983 B.A. University of Kansas, Lawrence, Kansas 8/1983-5/1987 M.D. University of Kansas School of Medicine, Kansas City, Kansas
POSTGRADUATE EDUCATION: Year Degree Institution 1987-90 Resident, Internal Medicine Baylor College of Medicine, Houston, Texas 1990-93 Fellow, Medical Oncology University of Texas, M.D. Anderson Cancer Center and Hematology, Houston, Texas 7-12/1991 Fellow, Hematology Baylor College of Medicine, Houston, Texas
ACADEMIC APPOINTMENTS: Month & Year Position Institution 7/1/04 Clinical Professor of Medicine University of Kansas School of Medicine Wichita, Kansas 7/1/99 Clinical Associate Professor University of Kansas School of Medicine Wichita, Kansas 7/1996 to 6/1998 Clinical Assistant Professor University of Kansas School of Medicine Wichita, Kansas 7/1994 to 6/1996 Assistant Professor University of Kansas School of Medicine Wichita, Kansas 7/1994 Adjunct Assistant Professor University of Texas, M.D. Anderson Cancer of Medicine Center, Houston, Texas 7/1993 to 6/1994 Assistant Professor & University of Texas, M.D. Anderson Cancer Assistant Internist Center, Houston, Texas 11/1991 to 6/1993 Junior Faculty Associate University of Texas, M.D. Anderson Cancer Center, Houston, Texas
Dennis F. Moore, Jr. Curriculum Vitae – Page 2
CERTIFICATION: Board Date Recertification American Board of Internal Medicine 9/1991 11/2001 Subspecialty (ABIM) Medical Oncology 11/1993 11/2001 Subspecialty (ABIM) Hematology 11/1996 PROFESSIONAL SOCIETIES AND AFFILIATIONS: (INCLUDING OFFICES HELD) Year Organization Office 2019 Cancer Research of Kansas Participating Physician 2014 Medical Society of Sedgwick County Membership & Ethics Committee 2009-10 Wesley Medical Center Internal Medicine Exec. Committee 2006 Kansas Chapter of American Society of Clinical Oncology President 2004 Journal of Rheumatology Reviewer 1999 American College of Physicians Fellow American Society of Internal Medicine Texas Society of Internal Medicine American Society of Hematology American Society of Clinical Oncology American Society for Blood and Marrow Transplantation Kansas Society of Clinical Oncology 1997 International Society for Hematotherapy and Graft Engineering Secretary 1994 National Cancer Institute (NCI) M.D. Anderson University of Rochester National Surgical Adjuvant Breast & Bowel Project (NSABP) Wichita Community Clinical Oncology Program (WCCOP) Board Member Leukemia Society of America (Kansas Chapter) Southwest Oncology Group (SWOG) HONORS AND AWARDS: Year Organization 2011 Platinum Award for ≥ 25 Patients in total accruals in NCI/Cancer Control Clinical Trials 2012 Plaque received for 2nd highest enrollment of patients on NCI Treatment and Cancer Control Clinical Trials (WCCOP Award). Washington University, St. Louis, Missouri 1981-82 President, Xi Chapter of Tau Kappa Epsilon 1983-87 University of Kansas School of Medicine Summer Research Fellowship Nell Educational Trust Scholarship 1987 Cieneguilla, Peru St. Francis Award, Parroquia de Cieneguilla Dennis F. Moore, Jr. Curriculum Vitae – Page 3
American Cancer Society 1990-91 Junior Investigator Award 1992-93 Research Fellowship University of Texas, M.D. Anderson Cancer Center 1990-91 Clifton D. Howe Award for Excellence in Clinical Oncology 1991-92 Competitive Research Award 1991-92 Sandoz Research Fellow Award (Dept. Hematology) 1992-93 Competitive Research Award 6/9/1993 Outstanding Chief Fellow (Special Award) Schwachmann Syndrome Foundation and Registry 4/1995- Advisory Board Leukemia Society of America 8/1997 Dr. Dennis Moore, Sr. Award 2/2001- Preferred Health Systems Specialty Advisory Board 5/2004 Clinical Professor – KU School of Medicine 4/2004 Loyal Order of the Moose 9/2005 Via Christi Regional Medical Center St. Luke Physician Recognition Award for the core value of Human Dignity
RESEARCH ACTIVITIES: 1. Brief statement of area of research interest: a. Lymphoma, hematologic malignancies and stem cell transplantation 2. Current Projects Underway: a. Completing work on lymphoma booklet b. Analyzing and writing manuscript for Phase II Lymphoma Trial for SWOG c. Collaborating with colleagues at MD Anderson Cancer Center to complete manuscripts regarding original observations in patients with lymphoma. 3. Grant Support Available: a. Previous grants b. American Cancer Society (1990-91, $10,000) c. Competitive Research Award, University of Texas MD Anderson Cancer Center: 1991-92, $3,300. d. Sandoz Research Fellow Award: 1991-92, $30,000. e. Competitive Research Award, University of Texas MD Anderson Cancer Center: 1991-92, $3,500. f. American Cancer Society Research Fellowship: 1992-93, $3,600.
CLINICAL ACTIVITIES: Dr. Moore spends more than 80 hours per week in patient care. He is actively part of the Catholic Ministries Winnebago-Omaha Nation in Nebraska. Dennis F. Moore, Jr. Curriculum Vitae – Page 4
TEACHING ACTIVITIES: Fall 1994 Oncologic Emergencies, Junior Tutorial Spring 1995 Oncologic Emergencies, Junior Tutorial - 3 sessions Fall 1995 Oncologic Emergencies, Junior Tutorial - 3 sessions Spring 1996 Oncologic Emergencies, Junior Tutorial - 3 sessions Fall 1996 Oncologic Emergencies, Junior Tutorial - 3 sessions Spring 1997 Oncologic Emergencies, Junior Tutorial - 3 sessions Fall 1997 Oncologic Emergencies, Junior Tutorial - 3 sessions Spring 1998 Oncologic Emergencies, Junior Tutorial - 3 sessions Spring 1995 4 months Resident Oncology Attending Fall 1995 2 months Resident Oncology Attending Spring 1996 5 months Resident Oncology Attending Fall 1996 4 months Resident Oncology Attending Spring 1997 3 months Resident Oncology Attending Fall 1997 3 months Resident Oncology Attending Spring 1998 5 months Resident Oncology Attending Fall 1998 4 months Resident Oncology Attending Spring 1997 7 lectures for Residents' Core Curriculum Series
ADMINISTRATION: Dates Organization University of Kansas School of Medicine 1985 Multidisciplinary Cancer Committee Representative 1984-85 Medical Students' Assembly 1984-85 Blood Drive-Hepatavax Information Committee 1984-86 Jayhawker MD Yearbook Committee University of Kansas School of Medicine-Wichita 1986-87 Community Relations Committee Representative 1986-87 Research Committee University of Texas, M.D. Anderson Cancer Center 1992-93 Chief Fellow 1993-94 Lymphoma Section Clinic Liaison to Office of Managed Care 1993-94 Clinic Chief, Section of Lymphoma 1993-94 Committee on Managed Care 1993-94 Ad Hoc Committee on Marketing 1994 Alternate, Physician Advisor for Section of Bone Marrow Transplantation
Dennis F. Moore, Jr. Curriculum Vitae – Page 5
PUBLISHED MANUSCRIPTS: 1. Moore D: The Importance of the Monocyte in Patients with Breast Cancer. 1984 Medical Student Research Training Program, KUMC 1984 Fall; 5: 296-323. 2. Pazdur R, Bready B, Moore DF Jr: Clinical Trials of Fluorouracil with Alpha-Interferon in Advanced Colorectal Carcinomas. Semin Oncol 1991 October; 18 (5 Suppl 7):67-70. 3. Pazdur R, Moore DF Jr, Bready B: The Modulation of Fluorouracil with Recombinant Alpha Interferon: The M.D. Anderson Clinical Trial. Semin Oncol 1991; 18 (Suppl 7):67-70. 4. Pazdur R, Moore D, Bready B: Modulation of Fluorouracil with Recombinant Alpha Interferon: M.D. Anderson Clinical Trial. Semin Oncol 1992; 19 (2 Suppl 3):176-179. 5. Moore DF Jr, Pazdur R, Daugherty K, Tarassoff P, Abbruzzesse JL: Phase II Study of Gemcitabine in Advanced Colorectal Carcinoma. Invest New Drugs 1992 Nov; 10(4):323-325. 6. Moore DF Jr, Pazdur R: Phase I Study of 5-Fluorouracil with Folinic Acid Combined with Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor. Am J Clin Oncol 1992 Dec; 15(6):464-466. 7. Pazdur R, Newman RA, Newman BM, Fuentes A, Benvenuto J, Bready B, Moore D, Jaiyesimi I, Vreeland F, Raber MN: Phase I Trial of Taxotere (RP 56976, NSC 628503): Five-day Schedule. J Natl Cancer Inst 1992; 84:1781-1788. 8. Moore D, Pazdur R: Systemic Therapies for Unresectable Primary Hepatic Tumors. J Surg Oncol 1993; 3(Suppl):112-114. 9. Moore DF Jr, Cabanillas F: What Constitutes a ‘Cure’ in Lymphoma? Leuk Lymphoma 1993; 11(3-4):161-163. 10. Moore DL Jr, Sears DA: Pica, Iron Deficiency, and the Medical History. Am J Med 1994; 97:390-393. 11. Moore DF, Pazdur R, Abbruzzese JL, Ajani JA, Dubovsky DW, Wade JL 3rd, Belt RJ, Mangold C, Bready B, Winn RJ: Phase II Trial of Edatrexate in Patients with Advanced Pancreatic Adenocarcinoma. Ann Oncol 1994 Mar; 5(3):286-287. 12. Pazdur R, Moore DF, Bready B, Giannone L, Maldonado A, Lin YG, Fueger RH, Winn RJ, Levin B: Phase II Trial of Edatrexate in Patients with Advanced Hepatocellular Carcinoma. Ann Oncol 1994 Sept; 5(7):646-648. 13. Moore DF Jr, Pazdur R, Abbruzzese JL: A Phase II Trial of Intravenous Melphalan in Advanced Colorectal Carcinoma. Invest New Drugs 1994; 12:133-136. 14. Moore DF, Kalvakolanu DV, Lippman SM, Kavanagh JJ, Hong WK, Borden EC, Paredes-Espinoza M, Krakoff IH: Retinoic Acid and Interferon in Human Cancer: Mechanistic and Clinical Studies. Semin Hematol 1994; 31(Suppl 5):31-37. 15. Romaguera JE, Rodriguez MA, Hagemeister FB, McLaughlin P, Swan F, Moore DF Jr, Sarris AH, Younes A, Hill D, Cabanillas F: A Phase II Trial of Oral Etoposide with Mitoxantrone and Ifosfamide/Mesna Consolidated with Intravenous Etoposide, Methylprednisolone, High-dose Arabinoside, and Cisplatin as Salvage Therapy for Relapsing and/or Refractory Lymphomas. Invest New Drugs 1994; 12(3):217-222. 16. Romaguera JE, Sarris AH, Swan F Jr, Younes A, Hagemeister FB, McLaughlin P, Rodriguez MA, Moore DF Jr, Cabanillas F: Phase II Study of Protracted 5-Fluorouracil Infusion in Patients with Relapsing or Refractory Lymphoma. J Infus Chemother 1994; 4:173-176. 17. Moore DF Jr, Buescher S, Vadhan-Raj S: Interleukin-1 Alpha Administration Increases Oral Granulocytes and Epithelial Cells. J Infect Dis 1994; 169(6):1419-1420. Dennis F. Moore, Jr. Curriculum Vitae – Page 6
18. Duvic M, Moore D, Menter A, Vonderheid EC: Cutaneous T Cell Lymphoma in Association with Silicone Breast Implants and Polyurethane: A Report of Four Cases. J Am Acad Dermatol 1995 Jun; 32(6):939-942. 19. Moore DF Jr, Moulopoulos LA, Dimopoulos MA: Waldenstrom Macroglobulinemia Presenting as a Renal or Perirenal Mass: Clinical and Radiographic Features. Leuk Lymphoma 1995 Apr; 17(3-4):331- 334. 20. Younes A, Sarris A, Melnyk A, Romaguera J, McLaughlin P, Swan F, Rodriguez A, Hagemeister F, Moore D, North L, Smith TL, Cabanillas F: Three Hour Paclitaxel Infusion in Patients with Refractory and Relapsed Non-Hodgkin's Lymphoma. J Clin Oncol 1995; 13(3):583-587. 21. Moore DF Jr, Vadhan-Raj S: Sustained Response in Felty's Syndrome to Prolonged Administration of Recombinant Human Granulocyte Macrophage Colony-Stimulating Factor (rhGM-CSF). Am J Med 1995; 98(6):591-594. 22. Moore DF Jr, Pazdur R, Sugarman S, Jones D 3rd, Lippman SM, Bready B, Abbruzzese JL: Pilot Phase II Trial of 13-Cis-Retinoic Acid and Interferon-as Combination Therapy in Advanced Pancreatic Adenocarcinoma. Am J Clin Oncol (CCT) 1995 Dec; 18:(6):525-527. 23. Sarris AH, Younes A, McLaughlin P, Moore D, Hagemeister F, Swan F, Rodriguez MA, Romaguera J, North L, Mansfield P, Callendar D, Mesina O, Cabanillas F: Cyclosporin A Does Not Reverse Clinical Resistance to Paclitaxel in Patients with Relapsed Non-Hodgkin's Lymphoma. J Clin Oncol 1996; 14(1):233-239. 24. Beran M, Kantarjian H, O'Brien S, Koller C, Al-Bitar M, Arbuck S, Pierce S, Moore D, bburzzese JL, Andreeeff M, Keating M, Estey E: Topotecan, a Topoisomerase-1 Inhibitor, is Active in the Treatment of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. Blood 1996; 88:2473-2479. 25. Van Besien KW, de Lima M, Giralt SA, Moore DF Jr, Khouri IF, Rondon G, Mehra R, Andersson BS, Dyer C, Clearly K, Przepiorka D, Gajewski JL, Champlin RE: Management of Lymphoma Recurrence After Allogeneic Transplantation: The Relevance of Graft Versus Lymphoma Effect. Bone Marrow Transplant 1997 May; 19(10):977-982. 26. Reddy SP, Harwood RM, Moore DF, Grimm EA, Murray JL, Vadhan-Raj S: Recombinant Interleukin-2 in Combination with Recombinant Interferon-γ in Patients with Advanced Malignancy: A Phase 1 Study. J Immunother 1997; 20(1):79-87. 27. Moore DF Jr, Cabanillas F: Staging and Prognostic Factors in Non-Hodgkin’s Lymphoma. Oncology 1998 Oct; 12(10 Suppl 7):1-8. 28. Moore DF Jr, Cabanillas F: Overview of Prognostic Factors in Non-Hodgkin’s Lymphoma. Oncology 1998; 12(10 Suppl 8):17-24. 29. Weiss GR, Liu PY, Alberts DS, Peng YM, Fisher E, Xu MJ, Scudder SA, Baker LH, Moore DF, Jr., Lippman SM: 13-Cis-Retinoic Acid or All-Trans-Retinoic Acid Plus Interferon-α in Recurrent Cervical Cancer: A Southwest Oncology Group Phase II Randomized Trial. Gynecol Oncol 1998:71:386-390. 30. Pazdur R, Medgyesy DC, Dakhil SR, Moore DF Jr, Scalzo A, Hoff PM, Arbuck SG, Abbruzzese JL: Phase II Trial of 9-Aminocamptothecin (NSC 603071) Administered as a 120-Hour Continuous Infusion Weekly for Three Weeks in Metastatic Colorectal Carcinoma. Invest New Drugs 1999; 16(4):341-346. 31. Samlowski WE, LeBlanc M, Kuebler PJ, Mandanas RA, Mangan KF, Moore DF Jr, Schuller DE, Ensley JF: Evaluation of Tomudex in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Southwest Oncology Group Study. Invest New Drugs 1999; 16(3):271-274. Dennis F. Moore, Jr. Curriculum Vitae – Page 7
32. Moore DF Jr., Brown TD, LeBlanc M, Dahlberg S, Miller TP, McClure S, Fisher RI: Phase II Trial of Menogaril in Non-Hodgkin’s Lymphomas: A Southwest Oncology Group Trial. Invest New Drugs 1999; 17(2):169-172. 33. Poplin EA, Liu PY, Delmore JE, Wilczynski S, Moore DF Jr, Potkul RK, Fine BA, Hannigan EV, Alberts DS: Phase II Trial of Oral Etoposide in Recurrent or Refractory Endometrial Adenocarcinoma: A Southwest Oncology Group Study. Gynecol Oncol 1999; 74(3):432-435. 34. Hesketh PJ, Crowley JJ, Burris HA III, Williamson SK, Balcerzak SP, Peereboom D, Goodwin JW, Gross HM, Moore DF Jr, Livington RB, Gandara DR: Evaluation of Docetaxel in Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Southwest Oncology Group Phase II Trial. The Cancer J from Scientific American 1999; 5(4):237-241. 35. Macdonald JS, Jacobson JL, Modiano M, Moore DF Jr, Gandara DR, Schoder LE, Chapman RA: A Phase II Trial of Etoposide, Leucovorin, 5-FU, and Interferon Alpha 2b (ELFI) + G-CSF for Patients with Pancreatic Adenocarcinoma: A Southwest Oncology Group Study (SWOG-9413). Invest New Drugs 2000; 18:269-273. 36. Chauncey TR, Rankin C, Anderson JE, Chen I, Kopecky KJ, Godwin JE, Kalaycio ME, Moore DF Jr, Shurafa MS, Petersdorf SH, Kraut EH, Leith CP, Head DR, Luthardt FW, Willman CL, Appelbaum FR: A Phase I Study of Induction Chemotherapy for Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Mitoxantrone, Etoposide, and MDR Modulator PSC833: A Southwest Oncology Group Study 9617. Leukemia Research 2000; 24:567-574. 37. Siefker-Radtke AO, Millikan RE, Tu SM, Moore DF Jr, Smith TL, Williams D, Logothetis CJ: Phase III Trial of Fluorouracil, Interferon Alpha-2b, and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Metastatic or Unresectable Urothelial Cancer. J Clin Oncol 2002 Mar; 20(5):1361-1367. 38. Weick JK, Crowley JJ, Hussein MA, Moore, DF, Barlogie B: The Evaluation of Gemcitabine in Resistant or Relapsing Multiple Myeloma, Phase II: A Southwest Oncology Group Study. Invest New Drugs 2002 Feb; 20(1):117-121. 39. Saad ED, Kraut EH, Hoff PM, Moore DF Jr, Jones D, Pazdur R, Abbbruzzese JL: Phase II Study of Dolastatin- 10 as First-Line Treatment for Advanced Colorectal Cancer. Am J Clin Oncol 2002 Oct; 25(5):451-453. 40. Alberts SR, Townley PM, Goldberg RM, Cha SS, Moore, DFJ, Krook JE, Buckner JC, Fitch TR, Wiesenfeld M, Mailliard JA: Gemcitabine and Oxaliplatin for Metastatic Pancreatic Cancer: A North Central Cancer Treatment Group (NCCTG) Phase II Study. Ann Oncology 2002 Apr; 13(4):553-557. 41. Roscoe JA, Morrow GR, Hickok JT, Bushunow PW, Pierce HI, Flynn PJ, Kirshner JJ, Moore DF Jr, Atkins JN: The Efficacy of Acupressure and Acustimulation Wrist Bands for the Relief of Chemotherapy-Induced Nausea and Vomiting: A URCC CCOP Multicenter Study. J Pain Symptom Management 2003 Aug; 26(2):731-742. 42. Goyle KK, Moore DF Jr, Garrett C, Goyle V: Benign Metastasizing Leiomyomatosis: Case Report and Review. Am J Clin Oncol 2003 Oct; 26(5):473-476. 43. Hofman M, Morrow GR, Roscoe JA, Hickok JT, Mustian KM, Moore DF, Wade JL, Fitch TR: Cancer Patients’ Expectations of Experiencing Treatment-Related Side Effects. A University of Rochester Cancer Center Community Clinical Oncology Program Study of 938 Patients from Community Practices. Cancer 2004 Aug; 101(4):851-857. Dennis F. Moore, Jr. Curriculum Vitae – Page 8
44. Alberts SR, Schroeder M, Erlichman C, Steen PD, Foster NR, Moore DF, Rowland KM, Nair S, Tschetter LK, Fitch TR: Gemcitabine and ISIS-2503 for Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma: A North Central Cancer Treatment Group Phase II Trial. J Clin Oncol 2004 Dec 15; 22(24):4944-4950. 45. Loprinzi CL, Levitt R, Barton DL, Sloan JA, Atherton PJ, Smith DJ, Dakhil SR, Moore Jr DF, Krook JE, Rowland KM, Mazurczak MA, Berg AR, Kim GP: Evaluation of Shark Cartilage in Patients with Advanced Cancer: A North Cancer Clinical Trial Group Trial. Cancer 2005 Jul 1; 104(1):176-182. 46. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Hillard M, Lazarus HM, Hurd DD, McCoy J, Moore DF, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC: Standard Chemotherapy Compared with High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321. J Clin Oncol 2006 Feb 23; 24(6):929-936. Epub 2006 Jan 23. Erratum in J Clin Oncol 2006 Jun 10; 24(17):2687. Moore, Dennis F Jr (added). 47. Haddock MG, Swaminathan R, Foster NR, Alberts SR, Hauge MD, Martenson JA, Fitch TR, Stella PJ, Tenglin RC, Schaefer PL, Moore DF, Dakhil SR: Gemcitabine, Cisplatin and Radiation Therapy for Patients with Locally Advanced Pancreatic Adenocarcinoma: A North Central Cancer Treatment Group Phase II Study, N9942. J Clin Oncol 2007 Jun 20; 25(18):2567-2572. 48. Garces YI, Okuno SH, Schild SE, Mandrekar SJ, Bot BM, Martens JM, Wender DB, Soori GS, Moore DF, Kozelsky TF, Jett JR: Phase I North Central Cancer Treatment Group Trial-N9923 of Escalating Doses of Twice-Daily Thoracic Radiation Therapy with Amifostine and with Alternating Chemotherapy in Limited Stage Small-Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2007 Mar 15; 67(4):995-1001. 49. Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, Hussein MA, Appelbaum FR, Larson RA, Moore DF Jr, Tallman MS: Phase III Trial of Fludarabine Plus Cyclophosphamide Compared with Fludarabine for Patients with Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997. J Clin Oncol 2007 Mar 5; 25(7):793-798. Epub 2007 Feb 5. 50. Haddock M, Swaminathan R, Foster N, Hauge M, Martenson J, Camoriano J, Stella P, Tenglin R, Schaefer P, Moore D, Alberts S: Gemcitabine, Cisplatin, and Radiotherapy for Patients with Locally Advanced Pancreatic Adenocarcinoma: Results of the North Central Cancer Treatment Group Phase II Study N9942. J Clin Oncol 2007 Jun; 25(18):2567-2572. 51. Jatoi A, Martenson JA, Foster NR, McLeod HL, Lair BS, Nichols F, Tschetter LK, Moore DF Jr, Fitch TR, Alberts SR: Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation for Locally Advanced Esophageal Cancer: Phase II Results of Preliminary Pharmacologic and Molecular Efforts to Mitigate Toxicity and Predict Outcomes: North Central Cancer Treatment Group (N0044). Am J Clin Oncol 2007 Oct; 30(5):507-513. 52. Jatoi A, Dakhil SR, Foster NR, Ma C, Rowland KM Jr, Moore DF Jr, Jaslowski AJ, Thomas SP, Hauge MD, Flynn PJ, Stella PJ, Alberts SR: Bortezomib, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients with Metastatic Esophageal, Gastric, and Gastroesophageal Cancer: Phase II Results from the North Central Cancer Treatment Group (N044B). J Thorac Oncol 2008 May; 3(5):516-520. 53. Witzig TE, Geyer SM, Kurtin PJ, Colgan JP, Inwards DJ, Micallef IN, LaPlant BR, Michalak JC, Salim M, Dalton RJ, Moore DF Jr, Reeder CB: Salvage Chemotherapy with Rituximab DHAP for Relapsed Non-Hodgkin Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group. Leuk Lymphoma 2008 Jun; 49(6):1074-1080. 54. El-Osta HE, Yammine YS, Chehab BM, Fields AS, Moore DF, Mattar BI: Unexplained Hemopercardium as Presenting Feature of Primary Cardiac Angiosarcoma: A Case Report and a Review of the Diagnostic Dilemma. J Thorac Oncol 2008 Jul; 3(7):800-802. Dennis F. Moore, Jr. Curriculum Vitae – Page 9
55. Johnson EA, Marks RS, Mandrekar SJ, Hillman SL, Hauge MD, Bauman MD, Wos EJ, Moore DF, Kugler JW, Windschitl HE, Rowland KM, Bernath AM, Fitch TR, Soori G, Jett JR, Adjei AA, Perez EA: Phase III Randomized, Double-Blind Study of Maintenance CAI or Placebo in Patients with Advanced Non-Small Cell Lung Cancer after Completion of Initial Therapy (NCCTG 97-24-51). Lung Cancer 2008; 60(2): 200-207. 56. Inwards DJ, Fishkin PAS, Hillman DW, Brown DW, Ansell SM, Kurtin PJ, Fonseca R, Morton RF, Moore DF, Veeder MH, Stella PJ, Nikcevich DA, Wender DB, Fitch TR, Witzig TE: Long-Term Results of the Treatment of Patients with Mantle Cell Lymphoma with Cladribine (2-CDA) Alone (95-80-53) or 2-CDA and Rituximab (N0189) in the North Central Cancer Treatment Group. Cancer 2008; 113:108- 116. 57. Ansell SM, Inwards DJ, Rowland KM, Flynn PJ, Morton RF, Moore DF, Kaufmann SH, Ghobrial IM, Kurtin PJ, Mauer M, Allmer C, Witzig TE: Low-Dose, Single-Agent Temsirolimus for Relapsed Mantle Cell Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group. Cancer 2008 Aug; 113(3):508-514. 58. Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, Reilly JF, Loboda A, Nebozhyn M, Fantin VR, Richon VM, Scheithauer BW, Giannini C, Flynn PJ, Moore DF, Zweibel J, Buckner JC: Phase II trial of Vorinostat (SAHA) in Recurrent Glioblastoma Multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2009 Apr 23; 27(12):2052-2058. Epub 2009 Mar 23. 59. Le Q, Moon J, Redman M, Williamson SK, Lara PN, Goldberg Z, Gaspar LE, Crowley JJ, Moore DF, Gandara DR: Phase II Study of Tirapazamine, Cisplatin, and Etoposide and Concurrent Thoracic Radiotherapy for Limited-Stage Small Cell Lung Cancer: SWOG 0222. J Clin Oncol 2009 June 13; 27(18):3014–3019. Epub 2009 Apr 13. 60. Horn L, Dahlberg S, Sandler A, Dowlati A, Moore DF, Murren JR, Schiller JH: Phase II Study of Cisplatin Plus Etoposide and Bevacizumab for Previously Untreated, Extensive-Stage Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 2009 Dec 13; 27(35):6006- 6011. Epub 2009 Oct 13. 61. Zonder J, Crowley J, Hussein M, Bolejack V, Moore D, Whittenberger B, Abidi, Durie B, Barlogie B: Lenalidomide and High-Dose Dexamethasone Compared with Dexamethasone as Initial Therapy for Multiple Myeloma: a Randomized Southwest Oncology Group Trial (S0232). Blood 2010 Dec 27; 116(26:5838-5841. Epub 2010 Sep 27. 62. Barton DL, Atherton PJ, Bauer BA, Moore DF Jr, Mattar BI, Lavasseur BI, Rowland KM Jr, Zon RT, Lelindqwister NA, Nagargoje GG, Morgenthaler TI, Sloan JA, Loprinzi CL: The Use of Valeriana Officinalis (Valerian) in Improving Sleep in Patients who are Undergoing Treatment for Cancer: A Phase III Randomized, Placebo-Controlled, Double-Blind Study (NCCTG Trial, N01C5). J Support Oncol 2011 Jan-Feb; 9(1):24-31. 63. Loprinzi CL, Balcueva EP, Liu H, Sloan JA, Kottschade LA, Stella PJ, Carlson MD, Moore DF Jr, Zon RT, Levitt R, Jaslowski AJ. A Phase III Randomized, Double-Blind, Pacebo-Controlled Study of Pilocarpine for Vaginal Dryness: North Central Cancer Treatment group study N04CA. J Support Oncol 2011 May-Jun; 9(3):105-112. 64. Weroha SJ, Oberg AL, Ziegler KL, Dakhil SR, Rowland KM, Hartmann LC, Moore DF Jr, Keeney GL, Peethambaram PP, Haluska P: Phase II Trial of Lapatinib and Topotecan (Laptop) in Patients with Platinum-Refractory/Resistant Ovarian and Primary Peritoneal Carcinoma. Gynecol Oncol. 2011 July 22; 122(1):116-120. Epub 2011 Apr 22. 65. Purnell J, Palesh O, Heckler C, Adams M, Chin N, Mohile S, Peppone L, Atkins J, Moore D, Spiegel D, Messing E, Morrow G: Racial Disparities in Traumatic Stress in Prostate Cancer Patients: Secondary Dennis F. Moore, Jr. Curriculum Vitae – Page 10
Analysis of a National URCC CCOP Study of 317 Men. Support Care Cancer 2011 Jul 23; 19(7):899- 907. Epub 2010 Apr 23. 66. Jatoi A, Nieva JJ, Qin R, Loprinzi CL, Wos EJ, Novotny PJ, Moore DF Jr, Mowat RB, Bechar N, Pajon ER Jr, Hartmann LC: A Pilot Study of Long-Acting Octreotide for Symptomatic Malignant Ascites. Oncology 2012 10; 82(6):315-320. Epub 2012 May 10. 67. Blumenthal DT, Rankin C, Stelzer KJ, Spence AM, Sloan AE, Moore DF Jr, Padula GDA, Schulman SB, Wade ML, Rushing EJ: A Phase III Study of Radiation Therapy (RT) and 06-Benzyl-Guanine (06-BG) Plus BCNU Versus RT and BCNU Alone and Methylation Status in Newly-Diagnosed Glioblastoma (GBM) and Gliosarcoma: Southwest Oncology Group (SWOG) Study S0001. Intl J Clin Oncol 2014 Nov 19. Epub 2014 Nov 19. 68. O’Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S, Pitot HC, Shields AF, Landry JC, Ryan DP, Parda DS, Mohiuddin M, Arora A, Evans LS, Bahary N, Soori GS, Eakle J, Robertson JM, Moore DF Jr, Mullane MR, Marchello BT, Ward PJ, Wozniak TF, Roh MS, Yothers G, Wolmark N: Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Rectal Cancer: Surgical End Points From National Surgical Adjuvant Breast and Bowel Project Trial R-04. J Clin Oncol. 2014 June 5; 32(18):1927-1934. Epub 2014 May 5. 69. Lucas D, Ruppert A, Lozanski G, Dewald G, Lozanski A, Claus R, Plass C, Flinn I, Neuberg D, Paietta E, Bennett J, Jelinek D, Gribben J, Hussein M, Appelbaum F, Larson R, Moore D, Tallman M, Byrd J, Grever M: Cytogenetic Prioritization with Inclusion of Molecular Markers Predicts Outcome in Previously Untreated Patients with Chronic Lymphocytic Leukemia Treated with Fludarabine or Fludarabine Plus Cyclophosphamide: A Long-Term Follow-up Study of the US Intergroup Phase III Trial E2997. Leuk Lymphoma 2015 Mar 30:1-7. Epub 2015 Mar 30. 70. Rapp SR, Case LD, Peiffer A, Naughton MM, Chan MD, Stieber VW, Moore DF Jr, Falchuk SC, Piephoff JV, Edenfield WJ, Giguere JK, Loghin ME, Shaw EG: Donepezil for Irradiated Brain Tumor Survivors: A Phase III Randomized Placebo-Controlled Clinical Trial. J Clin Oncol. 2015 May 20; 33(15):1653-1659. Epub 2015 April 20. 71. Steensma DP, Dakhil SR, Novotny PJ, Sloan JA, Johnson DB, Anderson DM, Mattar BI, Moore DF Jr, Nikcevich D, Loprinzi CL: A Randomized Comparison of Once Weekly Epoetin Alfa to Extended Schedule Epoetin or Darbepoetin in Chemotherapy-Associated Anemia. Am J Hematol, 2015 Jul 6. (Epub ahead of print). 72. Moore JA, Moore MB, Samaniego F, Pinnix CC, Moore DF Jr: Small Lymphocytic Lymphoma Presenting with Hypopituitarism. Am J Med. 2016 Jan; 129(1): e9-e10. Epub 2015 Sep 5. 73. Allegra CJ, Yothers G, O’Connell MJ, Beart RW, Wozniak TF, Pitot HC, Shields AF, Landry JC, Ryan DP, Arora A, Evans LS, Bahary N, Soori G, Eakle JF, Robertson JM, Moore DF Jr, Mullane MR, Marchello BT, Ward PJ, Sharif S, Roh MS, Wolmark N: Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. J Natl Cancer Inst. 2015 Sep 14; 107(11). Erratum in J Natl Cancer Inst. 2016 Apr; 108(4). 74. Till BG, Li H, Bernstein SH, Fisher RI, Burack WR, Rimsza LM, Floyd JD, DaSilva MA, Moore DF Jr, Pozdnyakova O, Smith SM, LeBlanc M, Friedberg JW: Phase II Trial of R-CHOP plus Bortezomib Induction Therapy Followed by Bortezomib Maintenance for Newly Diagnosed Mantle Cell Lymphoma: SWOG S0601. Br J Haematol. 2016 Jan; 172(2): 208-218. Epub 2015 Oct 22. 75. Malhotra B, Rahal AK, Farhoud H, Moore DF Jr, Kallail KJ: Treatment of Recurrent Posttransplant Lymphoproliferative Disorder with Autologous Blood Stem Cell Transplant. Case Rep Transplant. 2015:801082. Epub 2015 Nov 25. Dennis F. Moore, Jr. Curriculum Vitae – Page 11
76. Peoples AR, Roscoe JA, Block RC, Heckler CE, Ryan JL, Mustian KM, Janelsins MC, Peppone LJ, Moore DF Jr, Coles C, Hoelzer KL, Morrow GR, Dozier AM. Nausea and disturbed sleep as predictors of cancer-related fatigue in breast cancer patients: a multicenter NCORP study. Support Care Cancer. 2017 Apr;25(4):1271-1278. doi: 10.1007/s00520-016-3520-8. Epub 2016 Dec 20. PubMed PMID: 27995318; PubMed Central PMCID: PMC5323277. 77. Witzig TE, Johnston PB, LaPlant BR, Kurtin PJ, Pederson LD, Moore DF Jr, Nabbout NH, Nikcevich DA, Rowland KM, Grothey A. Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non- Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU). Am J Hematol. 2017 Oct;92(10):1004-1010. doi: 10.1002/ajh.24824. Epub 2017 Aug 17. 78. Galanis E, Anderson SK, Miller CR, Sarkaria JN, Jaeckle K, Buckner JC, Ligon KL, Ballman KV, Moore DF Jr, Nebozhyn M, Loboda A, Schiff D, Ahluwalia MS, Lee EQ, Gerstner ER, Lesser GJ, Prados M, Grossman SA, Cerhan J, Giannini C, Wen PY. Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. Alliance for Clinical Trials in Oncology and ABTC. Neuro Oncol. 2018 Mar 27;20(4):546-556. doi: 10.1093/neuonc/nox161. 79. Jaoude DA, Moore JA, Moore MB, Twumasi-Ankrah P, Ablah E, Moore DF Jr. Glioblastoma and Increased Survival with Longer Chemotherapy Duration. Kans J Med. 2019;12(3):65-69. Published 2019 Aug 21. MANUSCRIPTS SUBMITTED BUT NOT YET ACCEPTED: 1. Pazdur R, Bready B, Moore D, Ajani JA, Abbruzzesse J, Sugarman S, Markowitz A, Jones D, Levin B: Phase II Trial of Isotretinoin and Recombinant Interferon in Metastatic Colorectal Adenocarcinoma. (submitted) 2. Jatoi A, Moore DF, Nguyen PL, Sloan JA, Kugler JW, Rowland KM, Soori GS, Wender DB, Fitch TR, Novotny PJ, Loprinzi CL: A Placebo-Controlled Double-Blind Trial of Etanercept for Cancer Anorexia/Weight Loss Syndrome: Results from N00C1 from the North Central Cancer Treatment Group. (submitted July 2006) 3. Jatoi A, Martenson JA, Foster N, McLeod HL, Lair BS, Nichols F, Tschetter LK, Moore DF, Fitch TR, Alberts SR: Paclitaxel, Carboplatin, 5-Fluorouracil and Radiation Therapy for Locally Advanced Esophageal Cancer: Phase II Results of Pharmacologic and Molecular Efforts to Mitigate Toxicity and Predict Outcomes (North Central Cancer Treatment Group Study, N0044). (submitted to Am J Clin Oncol 12/06) 4. Keller S, Moore DF, et al: Prospective Randomized Phase III Trial of Postoperative Adjuvant Therapy in Patients with Completely Resected Stage II-IIIA Non-Small Cell Lung Cancer. (ECOG E3501) (submitted 10/06) 5. Jatoi A, Moore DF, Foster NR, Ma C, Rowland KM, Gross HM, Jaslowski AJ, Alberts SR, Kugler JW, Windschitl HE, Flynn PJ, Stella PJ: Bortezomib, Paclitaxel, Carboplatin as a First-Line Regimen for Patients with Metastatic Esophageal Cancer: Phase II Results from the North Central Cancer Treatment Group (N044B). (November 2007). 6. Purnell JQ, Palesh O, Heckler C, Adams MJ, Chin N, Peppone L, Mohile S, Atkins JN, Moore DF, Spiegel D, Morrow GR: Prostate Cancer, Traumatic Stress, and Race: Secondary Analysis of a National URCC CCOP Study of 329 Men. (Submitted to Supportive Care in Cancer, November 2009) OTHER PUBLICATIONS: (letters to the author, book review, etc.) 1. Moore D, Cabanillas F: What Constitutes a Cure in Lymphoma? [Editorial] Leuk Lymphoma 1993 Oct; Dennis F. Moore, Jr. Curriculum Vitae – Page 12
11(304):161-163 2. Moore DR Jr, Buescher S, Vadhan-Raj S: Interleukin-1 Alpha Administration Increases Oral Granulocytes and Epithelial Cells. [Letter] J Infect Dis 1994; 169(6):1419-1420. 3. Moore DF Jr, Huber M, Lippman SM, Hagemeister FB: Merkel Cell Carcinoma as a Second Primary Tumor in a Patient with Non-Hodgkin’s Lymphoma. Cancer Bulletin 1995; 47:175-177. 4. Moore DF Jr, Swan F, Yau J, Rodriguez MA, McLaughlin P, Sarris A, Romaguera J, Younes A, Hagemeister FB, Cabanillas F: Cyclosporine Plus Doxorubicin, Vincristine and Etoposide in the Treatment of Refractory Non-Hodgkin’s Lymphoma: A Phase II Study. Clin Oncol R Coll Radiol 1995; 7(5):300-303. 5. Robbins WA, Meistrich ML, Moore D, Hagemeister FB, Weier HU, Cassel MJ, Wilson G, Eskenazi B, Wyrobek AJ: Chemotherapy Induces Transient Sex Chromosomal and Autosomal Aneuploidy in Human Sperm. Nat Genet 1997 May; 16:74-78. [Letter] BOOKS AND BOOK CHAPTERS: 1. Moore DF Jr, Andreeff M: The acute leukemias, in Pazdur R (ed): Medical Oncology: A Comprehensive Board Review. Philadelphia (Huntington, NY), PRR Inc, 1993, pp 3-28. 2. Moore DF Jr, Mitsuyasu R: HIV-associated malignancies, in Pazdur R (ed): Medical Oncology: A Comprehensive Board Review. Philadelphia (Huntington, NY), PRR Inc, 1993, pp 379-393. 3. Moore DF Jr, Lee JS: Staging classification and prognostic factors for non-small cell lung carcinoma, in Pass HI, Mitchell J, Johnson DH, Turrisi AT (eds): Lung Cancer: Principles and Practice. Philadelphia, JB Lippincott, 1995, pp 481-495. 4. Moore DF Jr, Vadhan-Raj S: Hematopoietic growth factors in bone marrow failure states, in Treatment of Radiation Injuries. New York, Plenum Press (in press). 5. Moore DF Jr, Lippman SM, Kalvakolanu DVR, Borden EC, Kavanagh JJ, Paredes-Espinoza M, Schleuniger U, Massimini G, Holdener E, Hong WK, Krakoff IH: Retinoic acid and interferon combination strategies in solid tumors: Rationale and results, in Differentiation Therapy. Rome, Serono Symposia Publications (in press). 6. Moore DF Jr (ed): Clinicians’ Guide to Lymphoma; PRR, Inc 1997. PUBLISHED ABSTRACTS: 1. Moore D, Pazdur R, Daugherty K, Gutterman J, Levin B: A Phase I Study of 5-Fluorouracil with Folinic Acid Combined with Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor. Proc Am Soc Clin Oncol 1991; 10:1121 (#318). 2. Moore D, Estey E: Prognostic Value of the Day 14 Bone Marrow Examination in Newly Diagnosed Acute Myelogenous Leukemia. Blood 1991; 78(Suppl 1):457a (#1820). 3. Pazdur R, Gomez J, Schmidt S, Bready B, Moore D Jr, Light S, Mott D, Zhi J, Satoh H, Min B: Phase I Pharmacokinetic Study of Fluorouracil (FU) and Recombinant Alpha-2A Interferon (IFN). Proc Am Soc Clin Oncol 1993; 12:152a (#408). 4. Jaiyesimi I, Pazdur R, Ho DH, Lassere Y, Moore D Jr, Bready B, Krakoff IH: Phase I Trials of UFT (Ftorafur plus Uracil) and Leucovorin: 28 Day Schedule. Proc Am Soc Clin Oncol 1993; 12:152a (#409). 5. Bready B, Pazdur R, Sugarman S, Abbruzzesse J, Jones D, Moore D Jr: Phase II Study of Recombinant Alpha-2a Interferon and Isotretinoin in Patients with Advanced Colorectal Carcinoma. Proc Am Soc Clin Oncol 1993; 12:214a (#652). Dennis F. Moore, Jr. Curriculum Vitae – Page 13
6. Moore D Jr, Pazdur R, Bready B, Giannone L, Lin YG, Maldonado A, Winn R: Phase II Trial of Edatrexate in Advanced Hepatocellular Carcinoma. Proc Am Soc Clin Oncol 1993; 12:216a (#653). 7. Moore D Jr, Pazdur R, et al: UFT and High Dose Leucovorin Every 28 Days: A Phase I Study. Proc Am Assoc Cancer Res 1993; 34. 8. Moore D Jr, Swan F, Yau J, Rodriguez MA, McLaughlin P, Hagemeister F, Romaguera J, Katz RL, Huh YO, Sniege N, Redman JR, Velasquez WS, Grenko RT, Ordonez N, Cabanillas F: Cyclosporine Plus Doxorubicin, Vincristine, and VP-16 in the Treatment of Refractory Non-Hodgkin's Lymphoma: A Phase II Study. Proc Am Soc Clin Oncol 1994; 13:389 (#1325). 9. Younes A, Sarris A, McLaughlin P, Romaguera J, Jendiroba D, Swan F, Rodriguez A, Hagemeister F, Moore D, Cabanillas F: Phase II Trial of Taxol Given as 3-Hour Infusion Schedule Every 3 Weeks in Relapsed Non-Hodgkin's Lymphoma (NHL). Proc Am Soc Clin Oncol 1994; 13:374 (#1267). 10. Carrum G, Moore D, Hagemeister FB, Crow MK, Cabanillas F: Clinical Features and Outcome for Patients (Pts) 60 Years and Older with Hodgkin's Disease (HD). Proc Am Soc Clin Oncol 1994; 13:389 (#1324). 11. McLaughlin P, Hagemeister FB, Sarris A, Romaguera J, Pate O, Younes A, Swan F, Moore D, Cabanillas F: Fludarabine, Mitoxantrone, and Dexamethasone (FND) for Recurrent Low-Grade Lymphoma (LGL): A Phase II Trial. Proc Am Soc Clin Oncol 1994; 13:387 (#1318). 12. Moore D Jr, Pazdur RP, Sugarman S, Jones D III, Lippman SM, Bready B, Abbruzzesse JL: Pilot Phase II Trial of 13-Cis-Retinoic Acid and Interferon-Alpha in Advanced Pancreatic Adenocarcinoma. Proc Am Soc Clin Oncol 1995. 13. Moore DF Jr, Hagemeister FB: Clinical Characteristics and Outcome of Hodgkin's Disease in 125 Patients 60 Years of Age and Older. Blood 1994; 84 (Suppl 1):163a (#637). 14. Sarris AH, Younes A, McLaughlin P, Moore D, Hagemeister F, Swan F, Rodriguez MA, Romaguera J, North L, Cabanillas F: Cyclosporin A Does Not Reverse Clinical Resistance to Paclitaxel (Taxol) in Patients with Relapsed Non-Hodgkin's Lymphoma. Blood 1994; 84 (Suppl 1):167a (#654). 15. Romaguera JE, Sarris AH, Swan F Jr, Younes A, McLaughlin P, Rodriguez MA, Moore DF, Cabanillas F: Phase II Study of 5-Fluorouracil by Protracted Infusion in Patients with Relapsing or Refractory Lymphoma. Blood 1994; 84 (Suppl 1):647a (#2573). 16. Moore DF Jr, Moore DF Sr, Johnson DB, Cannon MW, Whisman SA, Church PS, Palko W, Dakhil S, Hynes HE: Bethesda Unit Titer as a Prognostic Factor for Patients with Acquired Factor VIII Inhibitors. Blood 1994; 84(Suppl 1):680a (#2705). 17. Moore DF Jr, Moore DF Sr, Diener C, Armstrong L, Slavik M, Watson E, Martin L, Peterson M: Efficacy of Granisetron (Kytril) for Chemotherapy-Associated Nausea and Vomiting in a VA Teaching Hospital. Proc Am Soc Clin Oncol 1995; 14:534 (#1762). 18. Hewitt St, Moore DF Jr: Black (Hairy) Tongue as an Indicator of Poor Outcome in Patients with Advanced Malignancy. Proc Am Soc Clin Oncol 1995; 14:498 (#1631). 19. Moore DF Jr, Moore DF Sr, Johnson DB, Bluml P, Cannon MW, Dakhil SR, Palko W, Hynes HE: Interleukin-2 (IL-2) Therapy Following Autologous Blood and Marrow Transplantation in Burkitt's Lymphoma: Effect on Lymphocyte Subsets. Proc of Second Pan-Pacific Lymphoma Conference 1995. 20. Wu J, Moore D Jr, Stobaugh J, Slavik M: Pharmacokinetic Modeling of Etoposide (VP-16) Administered by Short Intravenous Infusion. Fifth Annual Research Forum, University of Kansas School of Medicine- Wichita, Book of Abstracts 1995; 5:6. Dennis F. Moore, Jr. Curriculum Vitae – Page 14
21. Wu J, Svojanovsky S, Moore D Jr, Stobaugh J, Slavik M: Pharmacokinetic Modeling of Taxol Administered by Clinically Used Intravenous Infusional Schedules. Fifth Annual Research Forum, University of Kansas School of Medicine-Wichita, Book of Abstracts 1995; 5:8. 22. Lee BG, Moore DF Jr, Fleming RH: Response to Immunomodulation in a Patient with Cardiac Transplant Associated Non-Hodgkin's Lymphoma (NHL): Role of Lymphocyte Sub-Populations in Serial Reduction in Immunosuppression. Presented to the American College of Physicians Kansas Regional Meeting, September 6-7, 1996, Overland Park, Kansas by E. Magana. 23. Nelson TL, Schulz TK, Moore DF Jr, Moore DF Sr, Hartman K, Rohlman V: Hemolytic Anemia Secondary to the Bite of a Brown Recluse Spider: Case Reports and a Review of the Literature. Presented to the American College of Physicians Kansas Regional Meeting, September 6-7, 1996, Overland Park, Kansas by T. Nelson. 24. Ramsey TC, Moore DF Jr: Evaluation of Hemolytic Anemias. Presented to the American College of Physicians Kansas Regional Meeting, September 6-7, 1996, Overland Park, Kansas by T. Ramsey. 25. Schmidt DR, Moore D Jr, Moore DF Sr, Kovach KL, Weber HP Jr: Severe Metabolic Acidosis Associated with the Therapeutic Use of Interleukin-2 in Non-Hodgkin's Lymphoma. Presented to the American College of Physicians Kansas Regional Meeting, September 6-7, 1996, Overland Park, Kansas by D. Schmidt. 26. Moore DF Jr, Schmidt DR, Moore DF Sr, Kovach KL, Weber HP Jr: Severe Metabolic Acidosis Associated with the Therapeutic Use of Interleukin-2 in Non-Hodgkin's Lymphoma. Blood 1996; 88 (Suppl 1): (#3868). 27. Moore DF Jr, Preti A, Tran SM, Hagemeister FB, Rodriguez MA, McLaughlin P, Romaguera J, Sarris A, Younes A, Moore DF Sr, Cabanillas F: Prognostic Implications Following an Indeterminate Non- diagnostic Workup of Lymphoma. Blood 1996; 88(Suppl 1): (#906). 29. Chauncey TR, Rankin C, Anderson JE, Godwin JA, Kalaycio M, Moore DF, Petersdorf SH, Shurafa MS, Kraut EH, Head DR, Slovak ML, Willman CL, Appelbaum FR: A Phase I Dose-Finding Study of Induction Chemotherapy for Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Mitoxantrone (M), Etoposide (E), and the MDR Modulator PSC833: Southwest Oncology Group Study #9617. Blood 1998; 92(10) (Suppl. 1):231a (#945). 30. Morrow GR, JT Hickok, Lindke JL, Moore DF Jr., Wichita CCOP, Rousey S, Metro-Minnesota CCOP, Banerjee TK, Marshfield Medical Research Foundation CCOP, Wade P, Greater Phoenix CCIOP, University of Rochester Cancer Center, CCOP Research Base, Rochester NY: Longitudinal Assessment of Fatigue in Consecutive Chemotherapy Patients: A URCC CCOP Study. Proceedings of ASCO 1999; 18:593a (2293). 31. Aguayo A, Kraut EH, Moore DF, Wright JJ, Jones D, Winn R, Pazdur R: Phase II Study of Dolastatin 10 Administered Intravenously Every 21 Days to Patients with Metastatic Colorectal Cancer. American Society of Clinical Oncology (ASCO) Proceedings 2000; 19:288a (#1127). 32. Kelly K, Crowley J, Presant C, Grevstad P, Bunn P, Wozniak A, Weiss G, Moore D, Raghaven D, Livingston R, Gandara D: A randomized Phase III trial of Paclitaxel Plus Carboplatin Versus Vinorebine Plus Cisplatin in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer: A Southwest Oncology Group Trial. J Clin Oncol 2001 Jul 1; 19(13):3210-3218. 33. Saad ED, Kraut EH, Paula HM, Moore DF Jr, Jones D, Pazdur R, Abbruzzese JL: Phase II Study of Dolastatin-10 as First-Line Treatment for Advanced Colorectal Cancer. Am J Clin Oncol (CCT), 2002; 25(5). Dennis F. Moore, Jr. Curriculum Vitae – Page 15
34. Alberts SR, Townley PM, Cha S, Moore DF Jr, Krook JE, Fitch TR, Sargent DJ, Goldberg RM: Oxaliplatin and Gemcitabine for Patients with Pancreatic Adenocarcinoma: a NCCTG Phase II Study. Proc of Am Soc Clin Oncol 2002; 21:152a. 35. Ghabach BS, Moore DF Jr,: Glanzmann’s Patient with Acute Intra-Abdominal Bleeding; Successful Use of Recombinant Factor VII. Blood 2003; 102:79b (#4024). 36. Ghabach BS, Moore DF, Jr,: Langerhans Cell Histiocytosis: A Variety of Clinical Presentations and Treatment Options. Blood 2003; 102:287b (#4869). 37. Ghabach BS, Moore DF, Jr: Waldenstrom Macroglobulinemia Presenting as a Gastric Mass. Blood 2003; 102:366b (#5191). 38. Roscoe JA, Morrow GR, Hickok JT, Bushunow P, Pierce HI, Flynn PJ, Kirshner JJ, Moore DF Jr., Atkins JN: The Efficacy of Acupressure and Acustimulation Wrist Bands for Chemotherapy-Induced Nausea and Vomiting: A University of Rochester Cancer Center CCOP. J Pain and Symptom Management 2003 August; 26 (#731). 39. Goyle KK, Moore DF Jr., Garrett C, Goyle V: Benign Metastasizing Leiomyomatosis. Am J Clin Oncol 2003 October; 25(5). 40. Hofman M, Roscoe JA, Hickok JT, Morrow GR, Moore DF, Wade JL, Fitch T: Impact of Information Sources on Expectation of Cancer Treatment Side Effects. A URCC CCOP Study. ASCO 12/15/03; Control/Tracking Number 04-AB-682-ASCO. 41. Witzig TE, Geyer SM, Salim M, Inwards DJ, Fonseca R, Kaufman SH, Kurtin PJ, Colgan JP, Call TG, Moore DF Jr: A Phase II Trial of the Rapamycin Analog CCI-779 in Previously Treated Mantle Cell Non-Hodgkin’s Lymphoma: Interim Analysis of 18 Patients. Blood 2003; 102(11), (#2374). 42. Flinn IW, Kumm E, Grever MR, Neuberg D, Dewald GW, Bennett JM, Paietta EM, Appelbaum FR, Larson RA, Hussein MA, Moore DF, Tallman MS: Fludarabine and Cyclophosphamide Produces a Higher Complete Response Rate and More Durable Remissions than Fludarabine in Patients with Previously Untreated CLL: Intergroup Trial E2997. Blood 2004 (suppl 1) 104:139a (# 475). 43. Garces YI, Okuno SH, Schild SE, Mandrekar SJ, Mailliard JA, Kahanic SP, Rao RM, Moore DF, Kozelsky TF, Jett JR: A Phase I/II NCCTG Trial of Escalating Doses of Twice Daily Thoracic Radiation Therapy (TRT) in Limited-Stage Small Cell Lung Cancer (LSCLC). Proc Am Soc Clin Oncol 23:16 (#7163), 661s, 2005. 44. Sandler A, Szwaric A, Dowlati A, Moore DF Jr, Schiller: A Phase II Study of Cisplatin Plus Etoposide Plus Bevacizumab for Previously Untreated Extensive Stage Small Cell Lung Cancer (E3501): A Trial of the Eastern Cooperative Oncology Group. Proc Am Soc Clin Oncol (#7564), 2007. 45. Galanis E, Jaeckle KA, Maurer J, Reid JM, Ames MM, Giannini C, Hardwick JS, Moore DF Jr, Zwiebel JA, Buckner JC: N047B: NCCTG Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Recurrent Glioblastoma Multiforme (GBM). Proc Am Soc Clin Oncol (#2004), 2007. 46. Jatoi A, Martenson JA, Foster N, McLeod HL, Lair BS, Brindle JS, Nichols F, Tschetter LK, Moore DF, Fitch TR, Alberts SR: Paclitaxel, Carboplatin, 5-Fluorouracil and Radiation for Locally Advanced Esophageal Cancer: Phase II Results of Pharmacologic and Molecular Efforts to Mitigate Toxicity and Predict Outcomes: NCCTG (N0044). Am J Clin Oncol. 2007 Oct; 30(5):507-13. 47. Micallef IN, Maurer MJ, Nikcevich D, Cannon M, Moore D, Kurtin P, Witzig TE: A Phase II Study of Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma. Proc Am Soc Clin Onc 2008; 26 (May 20s) (#8500). Dennis F. Moore, Jr. Curriculum Vitae – Page 16
48. Purnell J, Morrow G, Roscoe J, Jean-Pierre P, Atkins JN, Moore DF, Kasper LM: Disruptions in Activities of Daily Living for African American Prostate Cancer Patients Compared to Whites. (Submitted to ASCO, 2008). 49. Witzig TE, Geyer SM, Kurtin PJ, Colgan JP, Inwards DJ, Micallef IN, LaPlant BR, Michalak JC, Salim M, Dalton RJ, Moore DF Jr, Reeder CB: Salvage Chemotherapy with Rituximab DHAP for Relapsed Non-Hodgkin Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group. Leuk Lymphoma. 2008 Jun; 49(6):1074-1080. 50. El-Osta HE, Yammine YS, Chehab BM, Fields AS, Moore DF Jr, Mattar BI: Unexplained Hemopericardium as a Presenting Feature of Primary Cardiac Angiosarcoma: A Case Report and a Review of the Diagnostic Dilemma. J Thorac Oncol. 2008 Jul; 3(7):800-802. 51. Micallef IN, Maurer M, Nikcevich DA, Cannon MW, Schaefer E, Moore DF, Kurtin, PJ, Witzig TE: Final Results Of NCCTG N0489: Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma. J Clin Oncol 2009; 27(15s):(#8508). 52. Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, Reilly JF, Loboda A, Nebozhyn M, Fantin VR, Richon VM, Scheithauer B, Giannini C, Flynn PJ, Moore DF Jr, Zwiebel J, Buckner JC: Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study. J Clin Oncol. 2009 Apr 20; 27(12):2052-2058. Epub 2009 Mar 23. Erratum in J Clin Oncol. 2009 Jul 1; 27(19):3262-3263. 53. Le QT, Moon J, Redman M, Williamson SK, Lara PN Jr, Goldberg Z, Gaspar LE, Crowley JJ, Moore DF Jr, Gandara DR: Phase II Study of Tirapazamine, Cisplatin, and Etoposide and Concurrent Thoracic Radiotherapy for Limited-Stage Small Cell Lung Cancer: SWOG 0222. J Clin Oncol. 2009 Jun 220; 27(18):3014-3019. Epub 2009 Apr 13. 54. Johnston PB, LaPlant B, Kurtin P, Habermann T, Moore DF, Nabbout N, Nikcevich DA, Rowland KM, Witzig TE: Salvage Chemotherapy with Rituximab, Oxaliplatin, Cytosine Arabinoside and Dexamethasone (ROAD) in Patients with Relapsed CD20+ Aggressive B-Cell Lymphoma. J Clin Oncol 2009; 27(15s):(#8556). 55. Kim G, Foster N, Salim M, Flynn P, Moore DF, Zon R, Mowat R, Wiesentfeld M, McCullough A, Alberts S. N064B: Randomized Phase II Trial of Panitumumab, Erlotinib and Gemcitabine Versus Erlotinib-Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma. ASCO poster discussion. J Clin Oncol 29:2011 (suppl. 4); (#238). 56. Abou-Jaoude D, Moore JA, Moore MB, Twumasi-Ankrah P, Ablah E, Moore DF: Glioblastoma and Increased Survival with Longer Chemotherapy Duration. J Clin Oncol 31, 2013 (suppl; abstr e13006) 57. Case D, Naughton J, Stieber VW, Bayer GK, Bilodeau PA, Moore DF, Falchuk SC, Needles BM, Piephoff J, Edenfield WJ, Giguere JK, Erickson N, Loghin ME, Shaw EG, Rapp SR: Quality of Life (QOL) and Cognitive Status Among Irradiated Brain Tumor Survivors Treated with Donepezil or Placebo. J Clin Oncol 31, 2013 (suppl; abstr 2051). 58. Reddy PS, Rahal AK, Kallail KJ, Moore DF, Truong PV, Mattar BI, Cannon MW, Nabbout NH, Page SJ, Truong QV, Dakhil C, Deutsch JM, Dakhil SR: The Application of Next-Generation Sequencing in the Community Clinical Oncology Setting. J Clin Oncol. 34, 2016 (suppl; abstr e23145). 59. Choucair K., Mattar B, Truong Q, Koeneke T, Truong P, Dakhil C, Cannon M, Page S, Deutsch J, Carlson E, Moore D, Nabbout N, Kallail KJ, Dakhil SR, Reddy PS. “Liquid biopsy: a promising gateway to implementing precision medicine and clinical trials; a community-based oncology practice experience.” 2020 ASCO poster discussion.
Dennis F. Moore, Jr. Curriculum Vitae – Page 17
60. Algazi AP, Othus M, Daud AI, Lo RS, Mehnert JM, Truong TG, Conry R, Kendra K, Doolittle GC, Clark JI, Messino MJ, Moore DF Jr, Lao C, Faller BA, Govindarajan R, Harker-Murray A, Dreisbach L, Moon J, Grossmann KF, Ribas A. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Nat Med. 2020 Oct;26(10):1564-1568. doi: 10.1038/s41591-020-1060-8. Epub 2020 Oct 5. PMID: 33020646.
POSTER EXHIBITS: 1. Moore D Jr, Pazdur R, Bready B, Dubovsky D, Wade J III, Belt R, Winn R: Phase II trial of Edatrexate (10-EdAM) in Advanced Pancreatic Carcinoma. Proc Am Assoc Cancer Res 1993 May 20; 34 (#1202). [Poster presentation]; Orlando, FL 2. Moore D Jr, Andreeff M, Mahadevia R, Van N, Zhao S, Goodacre A, Jeha S, Vadhan-Raj S: Effects of the Fusion Protein PIXY321 on the Proliferation of Bone Marrow Cells in Patients with Diamond- Blackfan Anemia. Blood 1993 December 5; 82(Suppl 1):(#341). [Poster presentation]; St. Louis, MO. 3. Moore DF Jr, Van N, Andreeff M, Jeha S, Mahadevia R, Van N, Zhao S, Vadhan-Raj S: Effects of the Fusion Protein (PIXY321 on Proliferation of Bone Marrow (BM) Cells in BM Failure States. Proc Am Soc Clin Oncol 1994; 13:298 (#972). [Poster presentation]. 4. Dakhil SR, Hynes HE, Cannon MW, Johnson DB, Moore DF Jr: G-CSF Plus Ciprofloxacin in the Prevention of Sepsis in Patients with Severe Neutropenia Related to Chemotherapy. Blood 1994; 84(Suppl 1): 24a (#83). [Poster presentation]. 5. Witzig TE, Geyer SM, Salim M, Inwards DJ, Fonseca R, Kaufmann SH, Kurtin P, Colgan JP, Call TG, Moore, DF Jr, White WL: A Phase II Trial of the Rapamycin Analog CCI-799 in Previousley Treated Mantle Cell Non-Hodgkin’s Lymphoma: Interim Analysis of 18 Patients. Journal Am Soc of Hematology 2003; 102 643a (#2374). [Poster Presentation] Session:545-II. 6. Purnell J, Morrow GR, Roscoe JA, Jean-Pierre P, Atkins JN, Moore Jr. DF, Kasper LM: Disruptions in Activities of Daily Living for African American Prostate Cancer Patients Compared to Whites. Proc Am Soc Clin Oncol 2008. [General Poster Presentation] Session #17G. 7. Micallef IN, Maurer MJ, Nikcevich DA, Cannon M, Moore Jr. DF, Kurtin P, Witzig TE: A Phase II Study of Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma. Proc Am Soc Clin Oncol 2008; 26. Clinical Science Symposium #8500. 8. Micallef IN, Maurer MJ, Nikcevich DA, Cannon M, Moore Jr. DF, Kurtin P, Witzig TE: A Phase II Study of Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma. International Lymphoma Conference, June 4-7, 2008, Palazzo Dei Congressi, Lugano, Switzerland. 9. Moore D Jr. Randomized Phase II trial of Panitumumab, Erlotinib and Gemcitabine Versus Erlotinib- Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma. Am Clin Oncol (29):152:2639 May 20, 2011:4036. [Poster presentation] 10. Stevens PL, Lenihan DJ, Ky B, Wameke CL, Johnson MM, Abramson VG, Mayer IA, Adams PT, Campbell MG, Cheema PS, Moore DF, Yeshwant C, Carver JR, Fisch M: Prediction and Early Detection of Anthracycline-Related Cardiotoxicity Using Cardiac Biomarkers. J Clin Oncol 32:5s, 2014 (suppl; #9644). Dennis F. Moore, Jr. Curriculum Vitae – Page 18
11. Ky B, Wameke CL, Lenihan DJ, Cheema PS, Moore DF, Campbell MG, Yeshwant C, Adams PT, Krone R, Carver JR, Nasta S, Svoboda J, Schuster SJ, Reddy NM, Patel SM, Rieber AG, Johnson MM, Fisch M: Clinical Risk Prediction in Anthracycline Cardiotoxicity. J Clin Oncol 32:5s, 2014 (suppl; #9624) 12. Galanis E, Anderson SK, Miller CR, Sarkaria JN, Jaeckle KA, Buckner JC, Ligon KL, Ballman KV, Moore DF, Ahluwalia MS, Lee EQ, Gerstner ER, Lesser GJ, Prados M, Grossman SA, Giannini C, Wen PY: Phase II Trial of Vorinostat (VOR) Combined with Temozolomide (TMZ) and Radiation Therapy (RT) for Newly Diagnosed Glioblastoma (GBM) (Alliance N0874/ABTC-0902). J Clin Oncol 32:5s, 2014 (suppl; #2030). ORAL PRESENTATIONS 1. Scientific papers presented at national and international meetings: a. Oncology and Managed Care, Managed Care Symposium and Case Managers Meeting, Westin-Galleria Hotel, Houston, Texas: April 20, 1994. b. Clinical Characteristics and Outcome of Hodgkin's Disease in 125 patients 60 years of Age and Older, December 1-3, 1994, the American Society of Hematology meeting in Nashville, Tennessee (poster). c. Abdallah JG, Moore DF Jr, Minns GO: Enteric-Associated T-cell lymphoma (EATCL) as an Unusual Presentation of Helicobacter pylori Associate ‘MALT’ Lymphoma. Presented at the American College of Physicians Kansas Regional Meeting, September 8-9, 1995 in Wichita, Kansas by Dr. Abdallah. d. Interleukin-2 (IL-2) Therapy Following Autologous Blood and Marrow Transplantation in Burkitt's Lymphoma: Effect of Lymphocyte Subsets, July 25-28, 1995, Second Pan-Pacific Lymphoma Conference, Kapalua, Hawaii (poster). e. Tran SM, Moore DF Jr, Cabanillas F: Prognostic Implications Following an Indeterminate Non- diagnostic Workup of Lymphoma. Presented to the American College of Physicians Kansas Regional Meeting, September 6-7, 1996, Overland Park, Kansas by S. Tran. f. Lee BG, Moore DF Jr, Fleming RH: Response to Immunomodulation in Patients with Cardiac Transplant Associated Non-Hodgkin's Lymphoma (NHL): Role of Lymphocyte Sub-Populations in Serial Reduction in Immunosuppression. Presented to the American College of Physicians Kansas Regional Meeting, September 5-6, 1997, Wichita, Kansas by E. Magana. g. McKee JW, Moore DF Jr: Glioblastoma Multiforme: Is There Increased Incidence in Southwest Kansas? Presented to the American College of Physicians Kansas Regional Meeting, September 5-6, 1997, Wichita, Kansas by J. McKee, who won a second place award in the Residents competition. h. Medgyesy D, Dakhil S, Moore D, Scalzo A, Hoff PM, Abburzzese J, Winn R, Pazdur R: A Phase II Trial of a 5-day Continuous Infusion of 9-Aminocamptothecin (9-AC) Weekly for 3 Weeks in Patients with Advanced Colorectal Carcinoma. Proceedings of the Tenth Annual NIC-EORTC Symposium on New Drugs in Cancer Therapy, June 16-19, 1998, Amsterdam. i. Chauncey TR, Rankin C, Anderson JE, Godwin JA, Kalaycio M, Moore DF, Petersdorf SH, Shurafa MS, Kraut EH, Head DR, Slovak ML, Willman CL, Appelbaum FR: A Phase I Dose-Finding Study of Induction Chemotherapy for Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Mitoxantrone (M), Etoposide (E), and the MDR Modulator PSC833: Southwest Oncology Group Study #9617. Proceedings of American Society of Hematology Fortieth Annual Meeting, December 4-8, 1998, Miami Beach, Florida. j. Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Giannini C, Moore DF, Zwiebel JA, Buckner JC, Galanis E: Results of a Phase II Trial of Vorinostat in Patients with Recurrent Glioblastoma: Evidence of Post-Treatment Histone Acetylation in Tumor Tissue and Pharmacokinetic Analysis: North Central Cancer Treatment Group (NCCTG) Study N047B. 6th International Congress on Targeted Therapies, August 24-26, 2007. Dennis F. Moore, Jr. Curriculum Vitae – Page 19
k. Barton, D, Moore D Jr, Sloan J, Stella P, Bauer B, Morgenthaler T: The Evaluation of Valeriana Officianlis to Enhance Sleep and Fatigue in Cancer Survivors: NCCTG Trial N01C5. Multinational Association of Supportive Care, June 26–28, 2009, Rome, Italy. 2. Scientific papers presented at local and regional meetings: a. Neurocysticercosis, 4/90, Baylor College of Medicine City-Wide Infectious Disease. b. Castleman's disease, 8/90, Baylor College of Medicine City-Wide Hematology. c. Soft tissue sarcoma, 4/2/91, University of Texas M.D. Anderson Cancer Center Division of Medicine Grand Rounds. d. Small round cell tumor, 6/6/91, University of Texas M.D. Anderson Cancer Center Division of Medicine Grand Rounds. e. Fludarabine therapy and late opportunistic infections, 7/10/91, Baylor College of Medicine City-Wide Hematology. f. Aplastic anemia, 7/17/91, Baylor College of Medicine City-Wide Hematology. g. Sézary syndrome, cutaneous lymphomas, and review of HTLV-I as an etiologic agents, 9/91, Baylor College of Medicine City-Wide Hematology. h. PNH/Ham's Test and Kit Ligand, Fall 1991, Baylor College of Medicine Hematology Case Conferences. i. Hemolytic disease of the newborn and intrauterine transfusions, 11/13/91, Baylor College of Medicine City-Wide Hematology. j. Pica in iron deficiency anemia: case report and review of the literature, 1/22/92, Baylor College of Medicine City-Wide Hematology. k. An update on the acute leukemias, 7/20/92, St. Joseph Medical Center Grand Rounds. l. AIDS-associated malignancies, 7/23/92, Veterans Administration Medical Center Grand Rounds. m. Biomarkers in head and neck malignancies, 2/26/93, University of Texas M.D. Anderson Cancer Center Journal Club, Section of Head and Neck and Thoracic Medicine Oncology. n. Phase II study of edatrexate (10-EdAM) in advanced pancreatic adenocarcinoma, 3/93, University of Texas M.D. Anderson Cancer Center Protocol Meeting. o. PIXY321 in Diamond-Blackfan anemia, 12/1/93, Baylor College of Medicine City-Wide Hematology. p. AIDS-associated malignancies, 6/10/94, Temple Veterans Administration Medical Center Grand Rounds (Texas). q. Update on Lymphomas, 9/6/94, St. Francis Regional Medical Center Internal Medicine Grand Rounds. r. Update on Lymphomas, 9/16/94, University of Kansas School of Medicine-Wichita Grand Rounds. s. New Issues in Bone Marrow Transplant, 11/1/94, St. Francis Regional Medical Center Conference. t. Colon Cancer, 3/27/95, St. Joseph Medical Center Conference. u. Lymphoma, 4/24/95, St. Joseph Medical Center Conference. v. Adjuvant Chemotherapy for Breast Cancer, 8/30/95, Via Christi Regional Medical Center-St. Francis Campus Conference. w. Adjuvant Chemotherapy -- Current Issues, October 6, 1995, Twenty-seventh Annual J.H. Holt Memorial Academic Assembly-Via Christi Regional Medical Center-St. Francis Campus. Dennis F. Moore, Jr. Curriculum Vitae – Page 20
x. Panel Discussion: Use of Endoscopy vs Use of Radiology in GI/Colon Malignancies, October 6, 1995, Twenty-seventh Annual J.H. Holt Memorial Academic Assembly-Via Christi Regional Medical Center- St. Francis Campus. y. Leukemia Update, October 24, 1995, Via Christi Regional Medical Center-St. Francis Campus Grand Rounds. z. Current Knowledge in Tumor Markers, 10/26/95, Via Christi Regional Medical Center-St. Francis Campus Grand Rounds aa. Lung Cancer: Evaluation and Prognosis, December 18, 1995, Columbia Wesley Medical Center Grand Rounds. bb. Anemia, 3/3/97, Columbia Wesley Medical Center Geriatric Series. cc. Lymphomas, April 22, 1997, Via Christi Regional Medical Center-St. Francis Campus Grand Rounds. dd. Update on Prostate Cancer Screening and Management, 9/6/97, American College of Physicians Kansas Chapter Meeting, Wichita, Kansas. (State-of-the-Art Lecture) ee. Stem cell transplantation, 10/5/99, Via Christi Regional Medical Center-St. Francis Campus Grand Rounds. ff. Lung cancer, 1/24/00, Wesley Medical Center Noon Conference.
Updated: 10/2020